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Introduction 
The third issue of Material Matters™ in 2014 is focused on Polymers in 
Therapeutics and Nanomedicine. This issue covers a variety of topics 
including synthetic and natural polymers that deliver a therapeutic payload 
using stimuli-response, self-assembly, or electrospun fibers. 
The first article, by Carmen Scholz (USA), reviews poly(amino acid) block 
copolymers. These biocompatible polymers are inspired by the activity 
and capabilities of enzymes. By synthesizing PEGylated polymers using 
one or two amino acids, the resulting self-assembled polymeric micelles or 
membranes allow for drug delivery in a variety of configurations. They can 
also be used to enable attachment of a drug delivery system to a surface.
In our second article, Amit Singh and Mansoor M. Amiji (USA) review stimuli-responsive 
materials as intelligent drug delivery systems. There are a variety of smart materials that are 
able to be tuned to deliver a drug as a result of several different types of stimuli. Highlights 
include pH-, redox-, enzyme-, thermo-, light-, ultrasound-, magnetically, and electrically 
responsive polymers.
Sang Jin Lee, James J. Yoo, and Anthony Atala (USA), review electrospun nanoscale fibers 
used in drug or protein delivery systems in our third article. They highlight several different 
apparatus for electrospinning, as well as methods to control the fiber properties. The 
resulting scaffolds were shown to have the ability to deliver a variety of drugs and proteins 
in a controlled manner.
The fourth article, by Raphaël Riva and Christine Jérôme (Belgium), reviews chitosan as 
a platform for pharmaceutical applications. Chitosan is a natural polymer which can be 
used to encapsulate drugs and has been shown to improve the therapeutic efficiency and 
bioavailability, as well as enable targeted delivery. Specifically, chitosan has been used with 
difficult-to-deliver genes and hydrophobic drugs.
Each article in this issue is accompanied by a list of polymers available from Aldrich® 
Materials Science. Contact us at matsci@sial.com if you need any material that you cannot 
find in our catalog, or would like a custom grade for your development work. We welcome 
your new product requests and suggestions as we continue to grow our polymer offering.
About Our Cover
Polymers in therapeutics and nanomedicine allow for improved solubility, decreased 
toxicity, controlled release, and can help enable site-specific delivery. Polymers are used 
to generate numerous biomolecule–polymer conjugates, small molecule drug–polymer 
conjugates, supramolecular drug-delivery systems, and can be used as a platform for 
controlled release. This issue’s cover art artistically illustrates a variety of drug-delivery 
systems, including functionalized multivalent polymer micelles, well-defined nanostructures, 
and polyplexes flowing through a blood vessel.
Your Materials Matter
We welcome fresh product ideas. Do you have a material or compound you 
wish to see featured in the Aldrich® Materials Science line? If it is needed to 
accelerate your research, it matters. Send your suggestion to matsci@sial.com 
for consideration.
Bryce P. Nelson, Ph.D.  
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Professor Richard Hoogenboom at Ghent University (Belgium) has 
recommended the addition of functionalized poly(2-alkyl-2-oxazoline), 
or poly(2-oxazoline) polymers to our product portfolio for biomedical 
applications. This includes alkyne-terminated poly(2-ethyl-2-oxazoline) 
(Aldrich Prod. No. 778338). Poly(2-oxazoline) polymers demonstrate a 
lower critical solution temperature (LCST) behavior in aqueous solutions 
and can be used as thermo-responsive materials for biomedical 
applications because their transition temperatures are close to that of the 
human body.1,2,3 Poly(2-oxazoline) has also been used in various other  
bio-inspired methods and for polymer therapeutics.4,5 In particular, our 
alkyne-terminated clickable poly(2-oxazoline) products can be used as 
versatile building blocks for the construction of a large variety of complex, 
well-defined polymer architectures (including cyclodextrin core star-
polymers) as well as virus and peptide polymer conjugates.1,6,7
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yy  Mini-reviews of the technology help determine:
 - The right techniques
 - The right reagents
 - The right conditions
yy Controlled Radical Polymerization Tools:
 - New initiators
 - Reversible Addition/Fragmentation Chain Transfer (RAFT) agents
 - Atom Transfer Radical Polymerization (ATRP) ligands  
and monomers
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POLY(AMINO ACID) BLOCK COPOLYMERS 
FOR DRUG DELIVERY AND OTHER BIOMEDICAL APPLICATIONS
Carmen Scholz
Department of Chemistry, University of Alabama in Huntsville
Huntsville, AL 35899
Email: scholzc@uah.edu 
Introduction to Polyamino Acids:  
The Next Best Thing to Proteins
Humankind has utilized protein materials throughout its existence, 
starting with the use of materials such as wool and silk for warmth 
and protection from the elements and continuing with the use of 
recombinant DNA techniques to synthesize proteins with unique 
and useful properties. Proteins consist of amino acids linked in a pre-
determined and genetically-prescribed sequence. There are twenty 
amino acids found in naturally occurring proteins. Commonly known 
as the standard proteinogenic amino acids, the sequence of these 
building blocks form the basis of protein function. The specific function 
of the protein impacts the sequence and abundance of particular amino 
acids. For example, the protection of the Bombyx mori pupa within 
the silk cocoon is a primary natural function of silk protein. As can be 
expected, the very hydrophobic and chemically non-reactive glycine 
and alanine comprise 70% of the amino acids in silk protein. Enzymes, 
however, are proteins that perform significantly different functions and, 
as such, are comprised of a different set of amino acids. Enzymes fulfill 
biochemical catalytic functions and their amino acid sequence enables 
catalytic activity through the composition and molecular architecture 
of the catalytic pocket. The stability of the enzyme is maintained via its 
unique tertiary structure and the solubility of the enzyme in its (aqueous) 
medium of activity is guaranteed by functionalized amino acids that form 
the outside of the three dimensional structure. 
This capability to enable unique and highly-targeted biological function 
makes proteins ideal candidates for drug delivery systems because 
proteins have the ability to: 
yy Form an ideal “cradle” for a variety of therapeutic drugs, including 
delicate hydrophilic proteins or hydrophobic small molecules. 
yy Interact with, fold, and transport DNA. 
yy Deliver a therapeutic to a targeted location using site-specific 
interactions, exploit transmembrane transport mechanisms, and 
deliver a therapeutic payload to a specific site of action, free of  
side-effects. 
However, our ability to engineer protein structure as well as 
understanding the infinite resulting interaction possibilities is still in 
its infancy. Despite of our current understanding of the intricacies of 
proteomics, the synthesis of fault-free (i.e., sequence-correct) proteins in 
appreciable amounts is still unresolved. 
The limitations in our ability to synthesize proteins tailored for delivery 
of specific drugs has led researchers to concentrate on “the next best 
thing”: poly(amino acid)s (PAAs). While this category of polymers is 
also sometimes referred to as “polypeptides”, this author suggests the 
use of the term is slightly misleading because “peptide” refers to a 
polymeric structure with a specific amino acid sequence. However, in the 
macromolecules considered here, typically only two or three different 
amino acids are used for synthesis and no specific amino acid sequence 
is achieved. 
PAAs are similar to proteins (and peptides) in that they consist of amino 
acid building blocks linked by means of amide bonds. This backbone 
architecture and the use of naturally occurring l-amino acids for their 
synthesis ensure their biocompatibility. Subsequently, their potential 
degradation products are l-amino acids, which will be readily absorbed 
by the body. Most PAAs consist of no more than two different amino acids 
that are linked to yield either random or block copolymers. 
When l-amino acids are used in the synthesis of PAAs, the polymeric 
products retain the stereoregularity of the monomers. This results in the 
creation of isotactic PAA polymers. This is structurally very important 
as the stereoregularity is responsible for the formation of distinct 
secondary structures. Typically, helices are expected as secondary 
structures for isotactic polymers. The resulting PAA copolymers also 
exhibit the chemical characteristics of the l-amino acid building blocks, 
such as polarity, electrostatic, and solubility behavior. These physical 
characteristics are exploited when amphiphilic block copolymers are 
synthesized. Amphiphilic block copolymers readily undergo self-assembly 
into gels, micelles, membranes, vesicles, nanoparticles, nanogels, and 
other three-dimensional structures. The synthesis and utilization of PAA 
block copolymers is discussed in this article. 
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Synthesis of Poly(amino acid)s 
Poly(amino acid)s and their syntheses were discussed in detail by 
Kricheldorf.1 PAAs are typically synthesized by the ring-opening 
polymerization of amino acid N-carboxyanhydrides (NCAs) initiated by 
an amino-terminated reagent, as shown in Figure 1. Results indicate 
the polymerization follows a living, ring-opening polymerization. 
This polymerization technique allows for the synthesis of PAA block 
copolymers as well as random copolymers, making it highly versatile. If 
the amino acid NCAs are added successively to the initiator (the addition 
of the NCA of amino acid A followed by the addition of the NCA of amino 
acid B), AB block copolymers are formed. If the NCAs of the two amino 
acids are added to the initiator as a mixture, random copolymers are 
formed. Additional polymer architectures of varying complexity can be 
achieved due to the living nature of the polymerization. 
–CO2
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Figure 1. Schematic of NCA polymerization leading to the synthesis of PAA block copolymers and 
PAA random copolymers.
When synthesizing PAAs for drug delivery and biomedical applications, it 
is crucial to tightly control the molecular weight within a narrow range. 
This can be accomplished by employing living polymerization techniques 
to produce block copolymers. To do this, Hadjichristidis et al. employed 
high vacuum techniques to purify the monomers, solvents, and initiator. 
The polymerization was then performed in a specialized vessel that 
guaranteed absolutely anhydrous conditions.2 Deming et al. developed 
syntheses that use transition metal catalysts to gain control over the 
molecular weight and polydispersity of the synthesized PAAs.3 Our own 
studies have shown that the first few addition reactions (i.e., the addition 
of the first few amino acid building blocks to the initiator) are most crucial 
to controlling the reaction and producing PAAs of the desired molecular 
weight and polydispersity.4 In the beginning of the polymerization, the 
nascent oligomers are not yet long enough to form a helical structure, 
but tend to form β-sheets due to strong hydrogen bond interactions. 
The rigidity of these structures suppresses the ability of the growing 
chain to undergo continued nucleophilic attacks on NCA monomers 
and these small β-sheet structures have a tendency to precipitate out 
of the polymerization solution, effectively stopping the polymerization.5 
If the β-sheet formation is not kept under control, the resulting final 
product consists of a few long chains that exceed the intended chain 
length as determined by the Monomer:Initiator ratio and low molecular 
weight oligomers. 
It was found that urea effectively suppresses the hydrogen bond 
formation between nascent PAA chains. As a result, the premature 
precipitation of product is suppressed. This allows for the polymerization 
to follow a living mechanism.4 Because urea suppresses the formation 
of β-sheets, there is sufficient time for the amino acid chains to reach a 
length of about 10 repeat units, enabling formation of α-helices. Once 
the β-sheet stage is overcome, polymerization proceeds in a controlled 
manner, where chain ends remain reactive (living) and block copolymers 
can readily form (Figure 1).
Poly(amino acid) Block Copolymers: 
Concepts for Drug Delivery Systems
Amino acids have diverse chemical properties and can be subdivided 
according to the nature of their side chains, including those that are 
aliphatic, aromatic, sulfur-containing, and those that contain ionizable 
groups. When designing a PAA for use in drug delivery, amino acids are 
selected based on chemical properties that meet the needs of both 
the drug and the solvent environment. Typically, amphiphilic block 
copolymers are formed from a hydrophilic (ionizable) and a hydrophobic 
amino acid (Figure 1). This amphiphilicity will induce self-assembly of 
the block copolymer when exposed to a selective solvent.6 In the case of 
drug delivery, where polymers are exposed to an aqueous environment, 
the hydrophilic segment of the block copolymer forms the outer layer 
or corona of the self-assembled structure, while the hydrophobic block 
self-assembles into a tightly packed structure that functions as a “cargo 
compartment” for hydrophobic drugs (Figure 2A). 
Deming et al. studied the self-assembly and packing of PAA diblock and 
triblock copolymers and provided an excellent model to illustrate the 
polymer interactions and their subsequent self-assembly (Figure 2).7 
Specifically, they studied copolymers consisting of poly(l-Leu), a 
hydrophobic amino acid and poly(l-Lys), an ionizable amino acid. 
Polymers of the following general structures were prepared: diblock 
copolymers: p(l-Lys)-block-p(l-Leu) and triblock copolymers: p(l-Lys)-block-
p(l-Leu)-block-p(l-Lys), and individual blocks varied in length. The resulting 
block copolymers have a positively charged p(l-Lys) block that contributes 
to its solubility in water and where it forms a distorted (stretched) random 
coil. The hydrophobic p(l-Leu) block forms an α-helix as a secondary 
structure that is maintained when exposed to an aqueous environment. 
In the case of the triblock copolymers, there are two p(l-Lys) blocks that 
are adjacent to the p(l-Leu) block.
When used as drug delivery vehicles, amphiphilic diblock copolymers 
generally self-assemble into classic spherical polymeric micelles upon 
exposure to a selective solvent such as water (Figure 2A). In most cases, 
the hydrophobic segment packs tightly to avoid contact with the water 
and the hydrophilic segment readily solubilizes to form a shell or corona 
around the hydrophobic core. However, in the case p(l-Lys)-block-p(l-Leu) 
diblock copolymers the very stable p(l-Leu) helical structure, assembles 
into a stiff rod shape, which impedes the formation of a spherical packing 
structure and a flat lamellar packing of the rods (Figure 2B) predominates. 
The rods line up in parallel and are held in place through hydrophobic 
intermolecular interactions. However, the hydrophilic blocks with 
increasing chain lengths assume a stretched random coil configuration 
and fill increasing molar volumes. In addition, electrostatic repulsion 
between the positively charged p(l-Lys) chains renders the situation even 
more energetically unfavorable. As the chain length of the hydrophilic 
blocks increases, curved membranes are formed. These are the result of 
asymmetric packing of the hydrophilic blocks (Figure 2C). The resulting 
For questions, product data, or new product suggestions, contact us at matsci@sial.com.
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increase in corona volume is energetically favorable. Structures with 
curvature in two directions can give rise to the formation of polymeric 
giant unilamellar vesicles. The repulsive effect between the p(l-Lys) 
blocks can also be resolved by twisting the plane of the p(l-Leu) blocks 
into fibrils, (Figure 2D). While the helices of the p(l-Leu) blocks maintain 
parallel packing, the hydrophilic blocks gain volume by expanding around 
the forming fibrils which extend in one direction only.
A) B)
D)C)
Figure 2. Self-assembly arrangement of PAA di- and triblock copolymers into (A) spherical 
micelles; (B) flat membranes; (C) curved membranes, and (D) fibrils, with the cross section 
extending out of the plane of the paper and the insert depicting how the helices assemble into 
twisted fibers. Reprinted with permission from Ref. 7, Copyright 2004, American Chemical Society.
In the case of p(l-Lys)-block-p(l-Leu)-block-p(l-Lys) triblock copolymers, 
where the two hydrophilic blocks are covalently attached to the 
hydrophobic core curved structures (Figure 2C) will not form. Instead, 
asymmetric packing of the p(l-Lys) blocks is impossible and fibrils readily 
form. Both the curved and the fibrilar structure models can be used to 
explain the gelation behavior observed for the p(l-Lys)-block-p(l-Leu) 
and p(l-Lys)-block-p(l-Leu)-block-p(l-Lys) block copolymers.8 Due to their 
amphiphilic nature, these copolymer systems can be readily loaded with 
hydrophobic (in the core) as well as hydrophilic (in the corona) drugs. 
One can further expand on the above concept of PAA-based drug 
delivery systems, by using a macroinitiator to start the ring opening 
polymerization of amino acid NCAs. Poly(ethylene glycol) (PEG), is one of 
the most thoroughly investigated biocompatible polymers. With its large 
excluded volume, PEG conveys a “stealth character” to the structures to 
which it is attached. This essentially makes the structures “invisible” to 
adjacent protein molecules. The effectiveness of PEG to reduce protein 
interaction has been explained in physico-chemical terms by its low 
interfacial free energy in water and by its unique coordination with water 
molecules, as each PEG repeat unit coordinates with two to three water 
molecules. PEGylated PAA structures are used as drug delivery systems, 
employing polymeric micelles or nanoparticles with PEG to form the 
corona. They are also used to biocompatibilize surfaces of implantable 
devices intended to be in contact with protein-containing (bodily) fluids. 
In the case of drug delivery systems, PEGylation prevents uptake by 
the reticuloendothelial system and PEG-coated surfaces are efficient in 
suppressing biofouling. 
The synthesis of PEGylated PAAs follows the scheme presented in 
Figure 1, with R representing NH2-terminated PEG. For biomedical 
applications, PEGs with molecular weights of 2,000 to 10,000 Da are 
typically used to ensure renal clearance of degradation products. It is also 
possible to use bifunctional, α,ω-diamino PEGs as macroinitiators. The 
resulting block copolymers will have the PEG block in the middle, allowing 
the formation of interesting self-assembled molecular architectures, such 
as flower-like micelles. 
A) B)
Figure 3. Surface modification with PEGylated PAA. A) The multi-point attachment of the PAA 
chain to the surface (e.g., by the formation of covalent bonds between l-Cys (yellow) and a 
gold surface) with the PEG-block (blue) extending away from the surface, thereby conveying a 
stealth character. B) Attachment of amino acid oligomers by single-point attachment and their 
subsequent modification with PAA-based polymeric micelles. The X indicates reactive terminal 
side groups, e.g., amino groups in l-Lys. A covalent bond is established between the PAA oligomer 
and the PAA polymeric micelle.
PEGylated PAAs can be attached directly to a surface and this surface 
attachment can be utilized for drug delivery applications.9 The attachment 
of PEGylated PAAs containing (l-Cys) repeat units can be achieved using 
gold-covered surfaces.10 To do this, l-Cys NCA is typically copolymerized 
with another amino acid (shown in green in Figure 3A), such as l-Lys NCA 
or l-Glu NCA, to achieve the optimal spacing (dilution) of the reactive 
l-Cys residues. The l-Cys repeat units react instantaneously with gold 
surfaces. The repeating l-Cys units in each block copolymer chain result in 
multiple anchor points to the surface (Figure 3A). 
Because the PAA block functions as a multivalent anchor, the PEG block 
is free to extend away from the surface upon exposure to an aqueous 
environment. This architecture accomplishes two objectives: 1) PEG is 
strongly attached to the surface through multiple covalent thiol-gold 
linkages, and 2) the PAA block remains closely bound to the surface. These 
two factors contribute to the overall biocompatibility of the surface by 
masking “holes” that may form between individual PEG chains. It is well 
known the formation of dense polymer brushes is inherently difficult on 
surfaces using a “grafting to” method. This is because the concentration 
gradient built up by the already attached chains provides a strong kinetic 
hindrance against additional grafting. Furthermore, the large excluded 
volume that PEG exerts in an aqueous environment, while beneficial 
for preventing protein interactions, hinders the formation of dense PEG 
brushes in “grafting to” procedures even further. Figure 4 shows complete 
coatings are achieved on gold surfaces with both, PEG-block-p(l-Glu)110-
block-p(l-Cys)10 and PEG-block-poly((l-Glu)110-co-(l-Cys)10). The polymer 
architecture, PAA random copolymer vs. block copolymer, has little to no 
influence on the polymer morphology on the surface. The coatings are 
homogenous and pinhole-free. 




















Figure 4. 10×10 µm AFM phase images of gold surfaces coated with PEG-b-p(l-Glu)110-block- 
p(L-Cys)10 (A) and PEG-block-p((l-Glu)110-co-(l-Cys)10) (B). 
Another concept combines surface coating with the option of decorating 
the surface with PAA-based polymeric micelles that could be drug-loaded; 
the concept is schematically depicted in Figure 3B. In this procedure, 
oligo-(l-Lys) was attached covalently to the gold surface by a terminal 
thiol group, which is the result of using cysteamine as the initiator in the 
ring-opening polymerization of l-Lys NCA. Subsequently, the surface 
was decorated with micelles prepared from PEGylated PAAs (HOOC-CH2-
PEG114-block-poly(Bz-l-Glu)13) that carry carboxyl groups in their corona 
and were, therefore, reactive toward p(l-Lys).11 Terminal carboxyl groups 
in the poly(Bz-l-Glu) side chains are protected as a benzyl ester to achieve 
the amphiphilicity that drives micellization. The resulting micelles are 
maintained due to the strong hydrophobic interaction of the benzyl 
groups in the micelle core. The micelles were covalently attached to the 
poly(l-Lys) using an amide linkage that formed between the terminal 
carboxyl groups of the polymeric micelles and the amino functions of 
poly(l-Lys), shown in Figure 5.
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20 deg






Figure 5. 10×10 µm AFM phase image of a gold surface coated with thiol-terminated p(l-Lys)15 
and decorated with polymeric micelles formed by HOOC-CH2-PEG114-block-p(Bz-l-Glu)13. 
Summary
The synthesis and application of PAA block copolymers in drug delivery 
and surface modification of biomedical products was discussed. Various 
self-assembly structures, including spherical polymeric micelles and 
membranes which enable gel formation, were examined. It was shown 
amino-terminated PEG can be used as a macroinitiator in the synthesis of 
PAAs, yielding block copolymers. PEGylated PAAs also self-assemble into 
polymeric micelles. Furthermore, if the PAA segment contains an amino 
acid that is reactive toward a surface (e.g., l-Cys reacts instantaneously 
with gold), the PAA block can be employed as a multi-point anchor to 
attach PEG covalently in a dense packing by a “grafting to” method to 
a surface. In a different surface modification approach, PAA oligomers 
attached covalently to a surface can be further decorated with PAA 
polymeric micelles, enabling attachment of a drug delivery system to 
a surface.
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Triblock Copolymers
For more information on this product line, visit aldrich.com/block.
BAB Triblock Copolymers













PEG average Mn900 
PLA average Mn1,500 
average Mn (1,500-900-1,500) 
< 1.2 PDI <12 months 659630-1G
PEG average Mn10,000 
PLA average Mn1,000 
average Mn (1,000-10,000-1,000) 





















PEG average Mn1,000 
PLGA average Mn2,200 
average Mn (1,100-1,000-1,100) 


















PEG average Mn5,000 (DCM, PEO) 
PLCL average Mn5,700 
average Mn (1,000-10,000-1,000) 





















PEG average Mn1,000 
PLGA average Mn2000 
average Mn (1,000-1,000-1,000) 
< 1.2 PDI 1-2 weeks 764787-1G
Poly(ethylene glycol)s
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RO PCL average Mn ~2,500 
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PCL average Mn ~13,000 
PEG average Mn ~5,000 
average Mn ~18,000  (total)
≤ 1.4 PDI >12 months 570311-250MG
570311-1G
PCL average Mn ~32,000 
PEG average Mn ~5,000 
average Mn ~37,000  (total)
< 1.4 PDI >12 months 570338-250MG
570338-1G
PEG macroCTAs






H3C CH3 Ph S
n
average Mn 10,000 ≤ 1.1 PDI 772569-1G
Poly(ethylene glycol) methyl ether 4-cyano-









average Mn 10,000 ≤ 1.1 PDI 753033-1G
Poly(ethylene glycol) methyl ether (4-cyano-4-pentanoate 








average Mn 5,400 ≤ 1.1 PDI 751626-1G
751626-5G








CH 3 CH 3 S
n
average Mn 5,000 ≤ 1.1 PDI 736325-1G
Poly(ethylene glycol) methyl ether (2-methyl-2-propionic acid 









average Mn 10,000 ≤ 1.1 PDI 752495-1G
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average Mn 10,000 ≤ 1.1 PDI 764930-1G
Poly(ethylene glycol) methyl ether (4-cyano-4-pentanoate 








average Mn 2,400 ≤ 1.1 PDI 751634-1G
751634-5G








CH 3 CH 3 S
n










average Mn 2,000 ≤ 1.1 PDI 764914-1G
Poly(ethylene glycol) methyl ether (4-cyano-4-pentanoate 








average Mn 1,400 ≤ 1.1 PDI 752487-1G
752487-5G
Synthetic Poly(amino acid)s
For more information on this product line, visit aldrich.com/polyaminoacid.
Homopolymers
Name Molecular Weight Prod. No.









Poly-dl-lysine hydrobromide 1,000-4,000 P0171-100MG



























Poly-(α,β)-dl-aspartic acid sodium salt 2,000-11,000 P3418-100MG
P3418-1G
Poly-d-glutamic acid sodium salt 2,000-15,000 P9917-100MG
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Name Molecular Weight Prod. No.















Poly-l-glutamic acid sodium salt 750-5,000 P1943-100MG
Poly(l-lactide) 85,000-160,000 P1566-5G




Poly-l-lysine, succinylated >50,000 P3513-100MG
P3513-1G
Poly-l-glutamic acid sodium salt 1,500-5,500  P1818-25MG
P1818-100MG
Poly-dl-ornithine hydrobromide 15,000-30,000 P0421-100MG
P0421-250MG
Poly-l-arginine hydrochloride 15,000-70,000 P7762-10MG
P7762-50MG
P7762-100MG
Poly-dl-lysine hydrobromide 25,000-40,000 P9011-25MG
P9011-100MG




Poly-d-lysine hydrobromide 4,000-15,000 P6403-10MG
P6403-50MG
P6403-100MG
Poly-l-ornithine hydrobromide 5,000-15,000 P4538-10MG
P4538-50MG
P4538-500MG












Poly-dl-lysine hydrobromide >40,000 P4158-25MG
P4158-100MG
P4158-500MG
Poly-l-arginine hydrochloride >70,000 P3892-10MG
P3892-50MG
P3892-100MG
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Poly-d-lysine hydrobromide 150,000-300,000 P1149-10MG
P1149-100MG
P1149-500MG






Poly-l-glutamic acid sodium salt 50,000-100,000 81328-100MG




Poly-d-lysine hydrobromide 30,000-70,000 81358-500MG
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Copolymers
Name Molecular Weight Feed Ratio Prod. No.
Poly(Arg, Pro, Thr) hydrochloride 10,000-30,000 Arg:Pro:Thr (6:3:1) P9431-25MG
Poly(Ala, Glu, Lys, Tyr) hydrobromide 20,000-30,000 Ala:Glu:Lys:Tyr (6:2:5:1) P1152-10MG
P1152-25MG
Poly(d-Glu, d-Lys) hydrobromide 20,000-50,000 D-Glu:D-Lys (6:4) P7658-25MG
P7658-100MG
Poly(Glu, Ala) sodium salt 20,000-50,000 Glu:Ala (6:4) P1650-100MG
Poly(Glu, Ala, Tyr) sodium salt 20,000-50,000 Glu:Ala:Tyr (6:3:1) P3899-25MG
P3899-100MG
Poly(Glu, Lys, Tyr) sodium salt 20,000-50,000 Glu:Lys:Tyr (6:3:1) P4409-10MG
P4409-25MG
P4409-500MG




Poly(Lys, Tyr) hydrobromide 20,000-50,000 Lys:Tyr (4:1) P4659-10MG
P4659-25MG
P4659-250MG
Poly(Glu, Tyr) sodium salt 5,000-20,000 Glu:Tyr (4:1) P7244-25MG
P7244-250MG
Poly(Glu, Lys) hydrobromide 75,000-125,000 Glu:Lys (1:4) P8619-100MG
Poly(Glu, Tyr)−Agarose - Glu:Tyr (4:1) P6835-5ML
Poly(Glu, Lys) hydrobromide 150,000-300,000 Glu:Lys (1:4) P0650-100MG
Poly(Glu, Ala, Tyr) sodium salt 20,000-50,000 Glu:Ala:Tyr (1:1:1) P4149-10MG
P4149-25MG





Poly(Arg, Pro, Thr) hydrochloride 5,000-20,000 Arg:Pro:Thr (1:1:1) P9306-25MG
Poly(Lys, Tyr) hydrobromide 50,000-150,000 Lys:Tyr (1:1) P4274-100MG
Poly(Glu, Glu-OEt) 70,000-150,000 Glu:Glu-OEt (1:1) P4785-250MG
Poly(Glu, Tyr) sodium salt 20,000-50,000 Glu:Tyr (1:1) P0151-25MG
20,000-50,000 - 81357-50MG
Poly(d,l-lactide-co-glycolide) 66,000-107,000 lactide:glycolide (75:25) P1941-1G
P1941-5G
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Introduction
Materials science has revolutionized the central paradigm of drug 
delivery, especially for cancer therapeutics, such that the physicochemical 
properties of the delivery system can be customized to develop so-called 
smart or intelligent systems that can deliver the therapeutic molecule 
on-demand. Much of the advances in the design of materials for drug 
delivery has been inspired by a growing understanding of tumor 
microenvironments and the exploitation of the subtle differences in the 
tumor bio-milieu. Cancer is a complex disease involving many different 
cell types, extracellular matrices, immune factors, signaling molecules, 
and physiological phenomena. The significant diversity of the cell types 
involved in cancer poses a significant challenge for targeting a tumor 
with a therapeutic drug. Acquired multidrug resistance (MDR) to existing 
chemotherapies further compounds the problem, inevitably leading 
to poor clinical outcomes. The tumor microenvironment is remarkably 
diverse; it is characterized by a variety of characteristics, including 
abnormal tumor vasculature, absence of lymphatic drainage, hypoxia, 
lower pH gradient, redox environment, high interstitial pressure, and 
high protease activity.1 At the cellular level, the tumor is comprised not 
only of cancer cells but also a diverse population that includes stromal 
cells, endothelial cells, components of immune cells, and cancer stem 
cells (CSCs).2 These heterogeneities within the tumor impart survival 
advantages and promote tumor growth, and also help to progress and 
disseminate the disease to distant sites. Alternatively, subtle differences 
in tumor physiology can be used to stimulate a response using a smart 
polymer system, enabling the design of therapeutic strategies with 
tumor specificity.
Internally Regulated Systems
Internally regulated vectors (also known as self-regulated or closed-loop 
systems) respond to a stimulus from within the body such as pH, redox, 
presence of proteases, or other factors to regulate drug release. Change in 
the bio-milieu at the diseased site triggers a chemical or physical change 
in the delivery system, which leads to the release of the payload. The 
release profile is entirely dependent on the physiological status of the site 
of the disease and cannot be modulated externally. 
pH-Responsive Systems
pH-responsive systems take advantage of the significant variations in 
pH to stimulate localized drug delivery to different regions of the body 
such as the gastrointestinal tract, tumor microenvironment, or to the 
endosomal/lysosomal compartments of the cell (Figure 1). Cancer cells 
prefer aerobic glycolysis as their primary source of energy irrespective of 
the oxygen concentration. This leads to accumulation of lactate in the 
tumor microenvironment which lowers the pH in the extracellular matrix. 
This phenomenon is often referred to as the “Warburg effect”. This not 
only serves the incessant demand for energy of a rapidly dividing cancer 
cell but also supplies the essential precursors for other macromolecule 
biosynthesis.4 pH-responsive vectors are typically designed using 
polymers that contain ionizable weak acids or weak bases to exploit the 
acidic microenvironment for controlled drug delivery into the tumors. 
These materials depend on protonation and deprotonation for the 
selective solubility in aqueous media. Acrylic acid (AAc) (Aldrich Prod. 
No. 147230), methacrylic acid (MAAc) (Aldrich Prod. No. 155721), maleic 
anhydride (MA) (Aldrich Prod. No. M188), N,N-dimethylaminoethyl 
methacrylate (DMAEMA) and 2-(methacryloyloxy)ethyl dihydrogen 
phosphate are some examples of weak acids and their derivatives 
that have been explored while poly(amidoamine) (PAA or PAMAM) is a 
common example of a polymeric weak base that has been extensively 
used for the design of pH-responsive delivery vectors. Poly(β-aminoester) 
(PbAE) is another polymer that possesses strong pH dependent solubility 
and PbAE has also been used in the design of pH-responsive delivery 
systems. A comprehensive in vitro and in vivo study using pH-responsive 
poly(ethylene oxide)-PbAE (PEO-PbAE) copolymer system demonstrated 
higher apoptosis in MDA-MB-231 breast cancer cells and effectively 
accumulated into the SKOV3 human ovarian cancer xenograft model.5–7 
Several pH-responsive vectors have been suitable for delivery of biologics 
such as gene, siRNA, miRNA, peptides and proteins as well, which 




















Figure 1. Schematic representation of differential pH environment at the organ (A), tissue (B), and 
cellular (C) level that could be exploited by pH-responsive drug delivery systems. Reprinted with 
permission from Reference 8, American Chemical Society 2010.
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Redox-responsive Systems
Tumors exhibit characteristic oxidizing extracellular and reducing 
intracellular environments generating a redox potential that has become 
the driving force for the development of redox-responsive delivery 
vectors. Redox-responsive systems tend to lose their structural integrity in 
response to the significantly higher cytosolic and nucleus concentration 
of glutathione tripeptide (2–10 mM) compared to the extracellular 
matrix (2–20 µM). Due to this response, disulfide bonds (S–S) are the 
most studied redox-sensitive linkage used to develop polymer-, lipid- 
or protein-based delivery systems. Shell shedding copolymers such as 
PEG-S-S-poly(ε-caprolactone) (PEG-S-S-PCL), PCL-S-S-poly(ethyl ethylene 
phosphate) (PCL-S-S-PEEP), S-S-PAA-g-PEG, or dextran-S-S-PCL have 
been successfully employed as redox-responsive delivery systems with 
faster drug delivery kinetics. This improvement is evident by the in vitro 
activity of the payload and excellent in vivo tumor growth regression.10 
Our group has developed a thiolated gelatin-based protein nanoparticle 
system that demonstrated tremendous capability in delivering both small 
molecules and genes for targeting pancreatic cancer cells in pancreatic 
human adenocarcinoma bearing tumor xenografts.11 In a separate 
study, these nanoparticles were loaded with plasmid encoding vascular 
endothelial growth factor (VEGF-1) in an orthotopic MDA-MB-231 human 
breast adenocarcinoma model which resulted in reduced tumor growth 
as well as angiogenesis.12 Adopting a layer-by-layer (LbL) assembly 
approach, poly(vinylpyrrolidone) (PVP) (Aldrich Prod. No. 81430) coated 
on silica nanoparticles was used as a sacrificial template to form disulfide 
crosslinked poly(methacrylic acid) (PMA) capsules for use in the delivery 
of proteins and peptides for use as vaccines and as small-molecule 
anticancer drugs.10 
Enzyme-responsive Systems
Proteases are an integral part of tumor physiology. Cancer-associated 
proteases (CAPs) such as matrix metalloproteinases (MMPs), cathepsin, 
and urokinase plasminogen activators (uPAs) play a crucial role in tumor 
tissue remodeling and in disease progression, invasion, and dissemination. 
MMPs have been shown to be overexpressed in a majority of cancers 
and are generally accepted to be important contributors to cancer 
progression and invasiveness.13 As a result, enzyme-responsive vectors 
have been designed with an enzyme-specific peptide in order to trigger 
delivery when the substrate is degraded by the enzymatic activity within 
the tumors. One example of these specially designed enzyme-responsive 
vectors was the local delivery of chemotherapeutic drugs by application 
of a protease sensitive matrix. Cisplatin conjugated to a protease 
cleavable peptide CGLDD was further bound to a PEG-diacrylate hydrogel 
wafer. This approach resulted in prompt drug release in response to the 
presence of MMP-2 or MMP-9. Dextran-PVGLIG-methotrexate conjugate 
showed a similar response from the MMPs to release the drug and 
demonstrated tumor inhibitory effect in vivo.14 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) (Sigma Prod. No. 76548) with acetylated 
dipeptide (N-Ac-AA) along with dioleoyl trimethylammonium propane 
(DOTAP) and phosphatidylethanolamine (PE) has been used to make non-
fusogenic liposomes that turn fusogenic when activated by elastase or 
proteinase K, thereby improving the intracellular uptake.14 
In a similar approach, DOPE functionalized with PEG using a protease 
responsive linker (e.g., GPLGIAGQ) was blended with disteraoyl 
phosphatidylcholine (DSPC), cholesteryl chloroformate, and cholesten-
5-yloxy-N-(4-((1-imino-2-,β-D-thiogalactosyl ethyl)amino)butyl)
formamide (Gal-C4-Chol) to make liposomes with galactose on 
the surface for targeting hepatic cells. These galactose moieties are 
shielded by bulky PEG groups, which limit their uptake. However, in 
the presence of MMP-2, the peptide that links PEG to the liposomal 
surface is cleaved to expose the targeting ligand, facilitating their 
rapid uptake.14 In a more recent effort, a cholesterol-anchored graft 
polymer containing peptide GSGRSAGK (bearing consensus sequence 
for uPA) and acrylic acid was incorporated in liposomes made using 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC, Sigma Prod. 
No. P6354), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, Sigma 
Prod. No. P0763), and cholesterol (47.5:5:47.5 respectively) (Figure 2A). 
These liposomes with crosslinked polymers showed improved stability 
with resistance to osmotic swelling or leaking. In the presence of the 
enzyme, the crosslinking rapidly degraded; this caused drug release 
through swelling of the liposome (Figure 2B).15 Though the clinical 
application of these nanovectors is yet to be established, preclinical 
studies indicate that these systems hold tremendous promise in 
augmenting therapeutic efficacy of drugs that otherwise show poor 
bioavailability. 
A)
























Figure 2. A) Scheme showing the multiple steps involved in the synthesis of uPA-sensitive, 
polymer-caged liposomes. B) Proposed mechanism of action of the polymer-caged liposomes 
in response to presence of enzyme. Reprinted with permission from Reference 15, American 
Chemical Society 2011.
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Externally Regulated Systems
Externally regulated systems, also referred to as open-loop systems, 
are vectors whose drug delivery capability can be governed by a 
stimulus from outside the body. Since the duration and strength of the 
external stimulus can be precisely controlled, the drug release profile 
of these nanovectors can be temporally and spatially controlled to 
achieve an on-demand supply of the drug at a desired dose. Heat, light, 
sound, magnetic, and electrical stimuli have all been explored and are 
discussed below.
Thermo-responsive Systems
Thermo-responsive materials undergo a phase change below or above 
a particular temperature. These changes are referred to as lower or 
upper critical solution temperature (LCST or UCST), respectively. Such 
materials are insoluble above or below the critical temperature but 
transform to a completely soluble form upon crossing the transition 
temperature. Poly(N-isopropyl acrylamide) (PNIPAAm) is one such 
polymeric material that is not ideal for drug delivery applications. 
PNIPAAm becomes hydrophobic at 32 °C in water and at temperatures 
that are similar to physiological conditions. However, altering the side 
chains, the molecular weight of the polymer, the polymeric architecture, 
or copolymerizing with other hydrophilic or hydrophobic polymers 
enables customization of the transition temperature to suit biomedical 
applications. PNIPAAm derivative, therefore, have been explored 
extensively as a material for thermo-sensitive drug delivery vectors and 
have been incorporated into micelles, liposomes, hydrogels and nanogels, 
polymersomes, interpenetrating networks, films, and the surface of 
inorganic nanoparticles.16 Copolymers of PNIPAAm with poly(N,N-
diethylacrylamide) (PDEAAm), poly(N-vinylcaprolactone) (PVCL), PLGA, 
poly[2-(dimethylamino) ethyl methacrylate] (PDMAEMA), PEG, gelatin, and 
chitosan have been used for the delivery of chemotherapeutic drugs and 
biologics. Beside drug delivery, considerable efforts have been made to 
develop thermo-sensitive materials for use in other applications including 
surfaces and scaffolds for tissue growth and engineering, imaging, 
and diagnostics.17 
Light-responsive Systems
Light is a popular choice as an external stimulus since its intensity and 
penetration depth can be precisely controlled. As a result, light-sensitive 
materials have become increasingly popular as drug delivery systems. 
Azobenzene, o-nitrobenzene, coumarin, and pyrene derivatives are 
routinely used for devising light-responsive drug delivery vectors. Jiang 
et al. developed a UV-responsive micelle system with poly(ethylene 
oxide) (PEO) and poly(methacrylate) which included pyrene sidechains 
as diblock copolymers. The authors used Nile red dye (Sigma Prod. 
No. 19123) as a surrogate to demonstrate the efficient release of the 
payload as a function of irradiation time and illumination power.18 
UV-irradiation, however, is not conducive for biological applications, 
especially for prolonged periods. For this reason, alternative materials 
responsive to visible or NIR wavelengths are being explored. Inorganic 
nanomaterials, especially anisotropic noble metal nanoparticles, show 
excellent NIR absorption characteristics and have been used as light-
absorbing materials to facilitate drug delivery. Kang et al. used silica-
coated gold nanorods with strong absorption maxima around 850 nm 
as a template to polymerize crosslinked acrylamide on the surface of the 
nanoparticle. Doxorubicin (DOX) loaded particles showed enhanced cell 
cytotoxicity upon irradiation with NIR light (808 nm) but the nanoparticles 
that had not been irradiated or irradiation in the absence of nanoparticles 
showed little effect. These results confirmed light-mediated payload 
release.18 In a similar approach, Hribar, et al. developed a polymer-gold 
nanorod composite that allowed a controlled and precise release of small 
molecules (<800 Da) upon irradiation with NIR-light. The PbAE macromers 
(A6), tert-butyl acrylate (tBA) monomers, and 2-hydroxyethyl acrylate 
(10:20:70% w/w, respectively) were polymerized to form the polymer 
blend. A high concentration of gold nanorods and light-responsive 
material could then be loaded in the core of the polymer microparticles 
(Figure 3A–4C). In vitro release of loaded DOX demonstrated a strong 
dependence on the light irradiation (Laser ON) (Figure 3D) and generated 
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Figure 3. A) Environmental scanning electron micrograph of polymeric microspheres (MS) made 
of A6:HEA:tBA (10:20:70). The scale bar corresponds to 50 µm. B) Backscattered micrograph 
of the microsphere showing the embedded gold nanorods (bright spots, scale bar = 20 µm) 
and a magnified image of the highlighted area showing the nanorods within the microsphere 
(scale bar = 200 nm). C) Bright field and florescence images of the microsphere showing the 
microspheres. The DOX loaded microspheres show intense fluorescence (top panel, right) while 
those without DOX do not show any background fluorescence (bottom panel, right). Scale bar 
in all images corresponds to 100 µm. D) Cumulative drug release from the microspheres as a 
function of laser pulse (Wavelength = 808 nm) applied at physiological temperature (37 °C). 
E) Histogram plot of T6–17 cells activity after exposure to MS alone with laser and DOX-loaded MS 
with a laser pulse of 1 and 3 cycles (Laser power = 1.1 W, 5 min/cycle). Reprinted with permission 
from Reference 19, American Chemical Society 2011.
Ultrasound-responsive Systems
The intensity of ultrasound energy such as light can be tailored for its 
intensity and focused over a small area in the body. This maximizes the 
drug release efficiency and, therefore, is often referred as high intensity 
focused ultrasound (HIFU). Due to its wide application in clinical imaging 
and diagnosis, ultrasound-based on-demand drug releasing vectors are 
seen as a natural material for the development of “theranostic” delivery 
systems. Ultrasound energy mediates drug release from a delivery 
vector by three main mechanisms: (1) heat generation, (2) acoustic 
cavitation, and (3) acoustic radiation forces. Some of the important 
parameters which can influence the performance of ultrasound-based 
techniques include the time and nature of application. The rationale 
behind ultrasound-based delivery is largely regulated by heat generation; 
therefore, the nanoparticle delivery systems designed for ultrasound-
based delivery are similar in composition to thermo-responsive systems. 
Microbubble technology, initially developed for contrast enhancement 
in ultrasound imaging, has since been exploited for acoustic cavitation to 
alter cell permeability and has also been used as a delivery vehicle.20 
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Ibsen, et al. prepared nested liposomes synthesized by a method in which 
a microbubble was created within the liposome to impart ultrasound-
responsiveness and demonstrated that it could be used for delivery 
of both small and large molecules. Similarly, mRNA-lipoplex loaded 
microbubbles were employed as a vaccine to successfully transfect and 
express the reporter gene in dendritic cells. This led to a slight shift in 
maturation and, in turn, induced T-cell response.21 As a result, ultrasonic-
assisted delivery is an attractive approach with significant potential.
Magnetically Regulated Systems
Like thermo- and ultrasound-responsive vectors, delivery systems 
responsive to magnetic fields rely on the induction of hyperthermia to 
release the payload. The ability to direct and concentrate these vectors 
in a specific area of the body through the application of an external 
magnetic field gives an added advantage to such delivery systems. 
Traditionally, magnetic nanoparticles such as superparamagnetic iron 
oxide nanoparticles (SPIONs) are incorporated into polymeric, lipidic, 
or protein delivery systems to impart them with magnetic properties. 
SPIONs have also been extensively used as magnetic resonance imaging 
(MRI) contrast agents, and their presence in a delivery vector offers an 
imaging modality that possesses stimuli-responsiveness. SPIONs coated 
with the thermo-responsive polymer PNIPAAm and loaded with DOX 
showed a rapid drug release above the lower critical solution temperature 
(LCST) due to magnetic field induced hyperthermia but a slow sustained 
release below the LCST. In vivo studies in buffalo rats implanted with 
hepatocellular carcinoma revealed magnetically guided increased 
accumulation and drug release in tumors. This resulted in an improved 
contrast-based MR imaging and efficient therapeutic potential.22 
Majewski, et al. demonstrated the utility of the magnetically active vectors 
as a gene delivery system. Most importantly, the study demonstrated that 
internalized magnetic nanoparticles can be used for selective isolation of 
the transfected cells from the population.23 Due to the added versatility 
of the magnetically regulated delivery system, they are now often used 
to design dual and multiple stimuli-responsive vectors to harvest the 
benefits of individual stimuli-responsiveness.24
Electro-responsive Systems
Certain materials (organic and inorganic) exhibit conductive properties 
and can be used to design delivery systems that are responsive to an 
external electric field. Common examples of electro-sensitive materials 
for drug delivery include polypyrrole (PPy, Aldrich Prod. No. 577030), 
ferrocene, and carbon nanotubes. Weak electric pulses (~1 V) are 
generally used for such applications and these electric fields are preferred 
over other externally applied stimuli due to several advantages: an electric 
pulse is (1) easy to control and apply, (2) does not need sophisticated 
and elaborate instrumentation, and (3) can be easily integrated to design 
chip-based devices. Ge, et al. prepared dodecyltrimethylammonium 
bromide (DTAB) micelles with decyl alcohol as a cosurfactant, and PPy 
was polymerized in the hydrophobic core. These nanoparticles were 
then loaded with a thermo-sensitive PLGA-PEG-PLGA block polymer that 
showed temperature-dependent sol-gel transformation. The polymer 
exists as a solution at 4 °C but rapidly forms a gel at a physiological 
temperature of 37 °C. Daunorubicin and fluorescein were loaded into 
the nanoparticles that were embedded in the polymer matrix. The 
resulting material maintained its solid hydrogel form at body temperature 
and demonstrated an electric-pulse dependent drug release. The 
subcutaneously injected, soluble form rapidly forms a gel in FVB mice and 
successfully released the payload in vivo upon application of the electric 
pulse. In the control group, the absence of an external stimulus resulted 
in insignificant release of the cargo.25 Adopting a novel approach, Zhu, 
et al. grafted 4-(3-cyanophenyl) butylene (CPB) as an electric field-active 
“nanoimpeller” onto the wall of mesoporous silica. Due to their large 
inherent dipole moment, the grafted CPBs reorient under the influence 
of an applied electric field. The CPBs then rapidly release the guest 
molecules (ibuprofen) from their pores.26 
Future Perspectives
The plethora of available literature on stimuli-responsive delivery systems 
demonstrates the growing importance for these systems. However, a 
majority of these systems have not made it past the pre-clinical stage 
and only a handful of examples currently have entered clinical trials.27 The 
need for a precise control over the “response” to the applied “stimulus” 
makes their clinical translation challenging. The complex synthetic steps 
and formulation of multiple components further compounds the issue. 
The majority of stimuli-responsive delivery systems are still in the early 
stages of development and the optimization of the synthesis procedures 
is needed before they can transition into the clinical world. Accuracy and 
precision over the stimulus will also need improvement from preclinical 
to the clinical level. Externally applied “physical” stimuli are easy to 
control and manipulate but internal “biological” triggers are not as easily 
controlled. Tumors show considerable variation in their physiological 
status between patients, organs, or even the same tumors in different 
species. External stimuli, on the other hand, need improvement to 
achieve better tissue penetration without causing any damage, which 
would require the optimization of several contributing parameters.
Other factors can also have a negative impact on delivery systems for 
the stimuli-responsive vectors. The EPR effect that leads to accumulation 
of the delivery vectors into the tumor is a well-accepted phenomenon 
in preclinical studies but has not yet been confirmed in clinical settings. 
Additionally, a majority of diseases show a complex microenvironment 
consisting of diseased cells, tissue interstitium, immune cells and other 
structural cells of the tissue that limits the ability of the delivery system to 
access the desired target cells. These physical and physiological barriers 
further impede the optimal performance of these delivery systems. In 
the case of cancer, heterogeneity at the cellular and physiological levels 
significantly limits the ability of these vectors to access their targets. A 
majority of the stimuli-responsive systems discussed have been tested 
in vitro but few have in vivo applications, an aspect that needs immediate 
focus. The goal is to design simplified systems with positive stimuli-
responsive characteristics. This achievement will drastically improve 
the chances for clinical applications. Though several major hurdles are 
yet to be overcome, stimuli-responsive systems have ultimately shown 
tremendous promise as alternatives to the existing delivery approaches. 
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Introduction
Local delivery of bioactive molecules using an implantable device can 
decrease the amount of drug dose required as well as non-target site 
toxicities compared to oral or systemic drug administration.1-3 Recently, 
electrospinning techniques using high-voltage electrostatic fields to 
generate nanofibrous structures have been used to develop drug or 
protein-loaded electrospun nanofibrous constructs for use as a novel 
implantable delivery system. The biomimetic cellular environment 
provided by electrospinning technology resembles the extracellular 
matrix (ECM) of native tissues and allows for the controlled fabrication 
of nano- to micro-scale fibers with specific composition, structure, and 
biomechanical properties of the fibrous constructs.4-8 Recent studies 
have shown that electrospun fibers with inherently high surface-area-
to-volume ratio and high interconnectivity have a number of benefits, 
including:  (1) high drug loading efficiency; (2) the ability to overcome 
mass transfer limitations associated with most polymeric delivery systems; 
(3) the facilitation of drug diffusion; and (4) improvement of solubility of 
various bioactive molecules.9 Encapsulation of these bioactive molecules 
into electrospun fibers allows for localized delivery of antimicrobials, 
anti-inflammatories, antiscarring agents, antineoplastic agents, 
immunosuppressives, growth factors, cytokines, genes (DNA and RNA), 
enzymes, bacteria and viruses, and a number of other important bioactive 
ingredients to target sites. 
Electrospinning Apparatus
Electrospinning has been used extensively to synthesize nanofibers 
for various applications4,6,10-12 because it allows the precise control over 
the composition, structure, and mechanical properties of the resulting 
biomaterial. Electrospinning requires a high-voltage power supply, a 
syringe pump, a polymer solution to be spun, and a grounded collection 
surface. Polymer solutions are exposed to a high-voltage power supply 
and delivered with a syringe through a blunt-tip needle using a syringe 
pump. Nanofibers can be collected onto a specially designed grounded 
mandrel placed at a specific distance from the needle tip. Controlling 
certain variables such as polymer solution concentration, molecular 
weight, conductivity, surface tension, flow rate, distance, collector 
geometry, and rotation speed during electrospinning allows for the 
fabrication of fibers with a specific morphology, diameter, and alignment. 
The fabricated electrospun nanofibers possess unique features and 
properties, including an extremely high surface-area-to-volume ratio 
that enhances cellular interactions with their substrates. The process 
of electrospinning also allows localized delivery of a combination of 
bioactive molecules to cells over a prolonged period.10 Conservation of 
the structural integrity and bioactivity of the encapsulated drug or protein 
after the electrospinning process is critical; therefore, several modifications 
of the electrospinning apparatus are currently being explored to better 
enable the fabrication of improved drug delivery systems (Figure 1).3
A) B) C)
Figure 1. Illustrations of different electrospinning techniques for drug/protein delivery. A) Blend 
electrospinning, B) Emulsion electrospinning, C) Coaxial electrospinning, D) Core-shell structure 
nanofibers comprised of a poly(vinyl pyrrolidone) (PVP) shell and a polycarbosilane (PCS) core 
prepared by emulsion electrospinning,13 and E) Core-shell structure nanofibers composed of a 
poly(ε-caprolactone) (PCL) shell and a bovine serum albumin (BSA)-loaded poly(ethylene glycol) 
(PEG) core prepared by coaxial electrospinning.14
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Modulation of Controlled Release from 
Electrospun Nanofibers
Since the release of bioactive molecules occurs primarily by diffusion, it 
has been demonstrated that the release profile of bioactive molecules 
from electrospun fibers can be influenced by biodegradability, fiber 
diameters, hydrophilicity, hydrophobicity, and configuration.10 In a recent 
study conducted by our group, electrospun PCL/collagen type I scaffolds 
derived from calf skin and composed of various fiber diameters were 
fabricated under conditions in which the concentration of the solution 
(Figure 2), flow rate, needle diameter, and distance from the substrate 
were carefully controlled.6 The fabricated electrospun PCL/collagen 
scaffolds showed randomly oriented fibrous structures with a linear 
relationship between fiber diameter and solution concentration. Distance 























Figure 2. A) SEM images (×10K magnification) of electrospun PCL/collagen fibers with different 
solution concentrations. B) Average fiber diameters of electrospun PCL/collagen fibers 
depending on solution concentrations. 
Okuda et al. demonstrated the release profiles of 5,10,15,20-tetraphenyl-
21H,23H-porphine tetrasulfonic acid disulfuric acid (TPPS)-loaded or 
chromazural B (ChroB)-loaded electrospun fibers yielded different fiber 
diameters.15 For the TPPS-loaded fibers, the sustained release duration and 
stable quasi-linear release rate were measured as 2 h and 4.0 μg/cm2/h, 
respectively, for smaller fibers (160 nm), and as 4 h and 2.0 μg/cm2/h, 
respectively, for larger fibers (400 nm). Similarly, these parameters of 
ChroB-loaded fibers were measured as 1 h and 4.8 μg/cm2/h, respectively, 
for smaller fibers (150 nm) and as 3 h and 2.7 μg/cm2/h, respectively, for 
larger fibers (290 nm). Smaller fibers exhibited rapid drug release in the 
initial stage. Furthermore, no significant differences were observed with 
respect to the total amount of released drug and the fiber diameter or 
type of drug. These results demonstrated that the fiber diameter was 
inversely proportional to the drug release rate and had no measurable 
impact on the total quantity of drug delivered. 
We previously hypothesized that the hydrophilicity of protein-carrier 
materials can actively influence the extent to which water diffuses 
through the scaffold, which is directly related to the release kinetics of 
the protein released from the scaffolds.16 In order to achieve controllable 
delivery of proteins to target locations more efficiently, we developed 
a novel delivery system based on electrospun fibrous poly(lactide-co-
glycolide) (PLGA), with a 75:25 lactide-to-glycolide ratio and molecular 
weight of 117 kDa, scaffolds combined with variable concentrations 
of Pluronic® F-127 (PF-127, PEO-PPO-PEO block copolymer (Sigma 
Prod. No. P2443). PF-127, an amphiphilic triblock copolymer, provides 
hydrophilicity to the polymeric scaffolds. Hydrophilic fibrous scaffolds 
absorb more water; this property may facilitate diffusion of drug or 
protein molecules from the scaffold. In this experiment, we used BSA 
(Sigma Prod. No. 05470) and myoglobin (Sigma Prod. No. M5696) as 
model proteins to study the effects of hydrophilicity on the release of 
protein from electrospun nanofibrous scaffolds. The addition of PF-127, 
a hydrophilic polymer, to electrospun fibers significantly increased the 
initial burst of drug released (p ≤ 0.05) and caused a subsequent increase 
in the release rate. In vitro release profiles of BSA or myoglobin that 
were released from the electrospun PLGA nanofibers showed significant 
variations between fibers with different hydrophilicities (p ≤ 0.05) 
(Figure 3)16.
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Figure 3. Release profiles of single protein delivery from the electrospun PLGA/PF-127 scaffolds. 
Percentage of cumulative release of A) BSA and B) myoglobin from electrospun PLGA scaffolds 
with different concentrations of PF-127. The release of both BSA and myoglobin could be 
controlled by the scaffold hydrophilicity.16 
Dual Protein Delivery System Using 
Co-electrospinning
Previous efforts have primarily focused on the delivery of a single 
bioactive molecule; however, the ability to deliver multiple bioactives 
with distinct kinetics to drive tissue development to completion is more 
relevant to the clinical situation.17-21 The development of healthy tissues 
and organs is dependent upon the rapid remodeling of an established 
vasculature through the coordinated action of many bioactive molecules 
including growth factors, cytokines, among others.17 Moreover, sustained 
release of bioactive molecules with different release kinetics enables 
effective tissue regeneration,22 which mimics the actual in vivo tissue 
environment during regeneration and contributes to effective and rapid 
tissue regeneration.23,24
We have developed a novel dual-protein delivery system using 
electrospun PLGA/PF-127 fibrous scaffolds. These hydrophilic scaffolds 
have the potential to provide distinct sustained release profiles for 
multiple proteins. The hydrophilicity of the electrospun PLGA nanofibers 
can also be adjusted by changing PF-127 concentration during 
fabrication. Two model proteins, BSA and myoglobin, were incorporated 
successfully into the electrospun PLGA/PF-127 scaffolds and were released 
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gradually and in a sustained manner from the scaffolds (Figure 4).16 
Furthermore, the release patterns for these proteins were altered by 
varying the hydrophilicity of the PLGA/PF-127 composite scaffolds. 
This co-electrospinning technique can incorporate multiple factors 
by using two or more syringes and power supplies. It can be used to 
simultaneously electrospin two or more polymer components (Figure 5). 
This method has the potential to be an ideal method for the fabrication 
of smart biomaterial scaffolds for use in the delivery of multiple bioactive 
molecules in tissue engineering.
A) B)
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Figure 4. Release profiles of dual protein delivery from the electrospun PLGA/PF-127 scaffolds. 
Cumulative release amount of BSA (A,B) and myoglobin (C,D) from co-electrospun PLGA/PF-127 
scaffolds. 1) PLGA-only + PLGA with 2 wt% protein (BSA or myoglobin); 2) PLGA-only + PLGA/10% 
PF-127 with 2 wt% protein; and 3) PLGA with 2 wt% protein + PLGA/10% PF-127 with 2 wt% 
protein (B,D). There was no significant difference between (1) + (2) and (3). This indicates that the 





Figure 5. Fluorescent images of functionalized electrospun fibers with incorporating different 
fluorescence dyes, DiIC (red) and DiOC (green). Co-electrospinning technique showed mixed 
fibrous structures with red- and green-labeled fibers simultaneously.
Three-dimensional Tissue-engineered 
Scaffolds
Electrospinning has evolved as a powerful tool in tissue engineering. This 
fabrication technology provides the ability to control properties such 
as biomaterial composition, fiber diameter, fiber alignment, geometry, 
and the degree of drug/protein incorporation in a scaffold. Nanofibers 
generated by electrospinning can support the adhesion and proliferation 
of a wide variety of cell types. More importantly, these cells maintain 
their phenotypic and functional characteristics on these nanofibrous 
scaffolds.25 Additionally, a number of recent studies have demonstrated 
that micro- to nano-scaled topography directly affects the adhesion, 
proliferation, orientation (Figure 6),26 and survival of cells in culture.27 
Therefore, studies using electrospun nanofibrous scaffolds can advance 
our understanding of the topographical aspects of cellular interactions 
and guide future efforts in regenerative medicine toward improved 
tissue formation. Furthermore, these scaffolds can be functionalized by 
adding biochemical and mechanical cues such as surface modification 
with bioactive molecules to enhance cellular interactions for tissue 
engineering applications. While specific interactions between cells and 
functionalized electrospun scaffolds are not fully understood, knowledge 
gained with respect to the specific modifications that enhance cell 
adhesion, proliferation, and guidance of cells seeded on a scaffold, as 
well as those that could affect host cell infiltration, differentiation, and 
vascularization in vitro and in vivo will be crucial for the advancement of 
tissue engineering applications. 
Figure 6. Immunofluorescent images of F-actin of skeletal muscle cells on electrospun PCL/
collagen nanofibers:  A) culture dish, B) randomly oriented, and C) aligned electrospun nanofibers 
(×40 magnification). Laser confocal microscopy images of F-actin of skeletal muscle cells seeded 
on the D) randomly oriented and E) aligned electrospun nanofibers (×600 magnification).26
Conclusions and Future Outlook
Electrospinning has evolved as an important tool in drug/protein delivery 
by providing the ability to control material composition, fiber diameter, 
and geometry in order to affect the release profile of bioactive molecules 
released from electrospun fibers. Bioactive molecules can be incorporated 
into electrospun fibers using physical adsorption, blend electrospinning, 
emulsion electrospinning, coaxial electrospinning as well as surface 
immobilization after electrospinning. Moreover, nano-scaled fiber 
structures generated by electrospinning can be used to improve cellular 
interactions, including cell adhesion, proliferation, differentiation, and ECM 
production allowing the control of scaffold composition, structure, and 
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mechanical properties. The resulting electrospun nanofibrous scaffolds 
possess unique features and characteristics, including an extremely high 
surface-area-to-volume ratio that allows for enhanced cellular activities 
within the scaffolds. In addition, the high porosity and interconnectivity 
of the three-dimensional electrospun nanofibrous scaffolds provides a 
favorable environment for cell infiltration and attachment. The unique 
characteristics of electrospun nanofibers make these materials a highly 
promising vehicle for the future delivery of multiple bioactive factors for 
enhanced drug delivery and tissue engineering applications.
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Block Copolymers
Name Structure Molecular Weight PDI Degradation Time Prod. No.











PEG average Mn 2,000
PLA average Mn 2,200
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PEG average Mn2,000
PLGA average Mn15,000
average Mn 17,000  (total)
< 1.8 PDI 1-4 weeks 764760-1G
PEG Mn2,000
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< 1.5 PDI 1-4 weeks 764825-1G
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Introduction
The development of new medical devices and pharmaceuticals plays an 
integral role in the medical industry. Both natural and synthetic polymers 
possess benefits that make them valuable components in therapeutics. 
In fact, methods to encapsulate drugs in a polymer matrix have 
demonstrated improved therapeutic efficiency and bioavailability while 
preventing the drug degredation. In nanomedicine, the development 
of polymer-based nanocarriers was first initiated in response to the 
immunologic side reactions encountered with viral-based nanocarriers.1,2 
In this context, we will discuss the recent emergence of methods that use 
natural polymers and their derivatives as tools to achieve a high degree of 
biocompatibility with controlled biodegradability.3 
Chitosan for Biomedical Applications
There are several families of natural polymers available on the market. 
Chitosan is one particular example of a polymer that has been 
thoroughly studied during the last few decades and shown to be 
a non-toxic, semi-crystalline,4 biodegradable,5 and biocompatible6 
polysaccharide. Chitosan is a random copolymer of N-acetyl-glucosamine 
and glucosamine units obtained by the deacetylation of natural chitin, 
generally under alkali conditions at relatively high temperature (Figure 1).4 
Natural chitin is a renewable resource that can be extracted from the 
exoskeleton of crustaceans or insects. Chitin can also be obtained 
from non-animal sources, namely from the cell walls of mushrooms.7,8 
Generally, mushroom-derived chitosan (Aldrich Prod. No. 740500) 
displays a narrower molar mass distribution, and better traceability and 
















Figure 1. Chemical structure of chitosan.
The demonstrated biocompatibility and biodegradability of chitosan 
has rapidly paved the way for advancements in a number of biomedical 
applications9 including scaffolds for tissue engineering.10 For example, 
the three-dimensional porous structure of chitosan can be seeded with 
sensitive bioactive agents, including growth factors.11 Additionally, the 
combined hemostatic12 and antimicrobial13 properties of chitosan make 
it an outstanding candidate for use in wound dressings.14–15 In particular, 
these two intrinsic properties limit the risk of infection which, in turn, 
improves skin regeneration. The hydrophilic nature of chitosan makes it 
a suitable starting material for use in biodegradable and biocompatible 
hydrogels. The mechanical properties of pH-sensitive hydrogels can be 
adjusted by combining chitosan with simple additives like hydroxyapatite 
in order to meet specific application requirements.16
Chitosan for Pharmaceutical Applications
 In pharmaceutical applications, chitosan17 has been successfully applied 
in the development of drug carriers18–19 for controlled drug delivery. The 
presence of positive charges in chitosan has been shown to increase 
adhesion to mucosa and as a result, increase the retention time.20 The 
positively charged chitosan backbone also allows for the formation 
of stable electrostatic complexes with polyanionic macromolecules, 
such as polyphosphate21 or nucleic acids.22 As a result, the application 
of chitosan for DNA or RNA encapsulation in gene therapy is an area 
of significant research.23 Chitosan solubility is of critical importance 
and is pH dependent. Chitosan is water soluble below pH 6.5 due to 
the protonation of the primary amine group. When soluble chitosan 
is required at neutral pH, two possibilities are available; either the use 
of chitosan oligomers (Aldrich Prod. No. 523682), which are known to 
be highly soluble in water in a wide range of pH values, or the use of a 
chemically modified chitosan derivative. Particularly, the ethoxylation of 
the primary alcohol of both glucosamine and acetyl-glucosamine units 
leads to O-glycol-chitosan, a fully water soluble chitosan derivative.
Chitosan Derivatives for Gene Delivery
Effective non-viral delivery of nucleic acids has many challenges, 
including degradation via nucleases and a decrease in efficiency due to 
negative charges accumulated while crossing over cellular membranes. 
One approach to address these challenges is the formation of polymer 
complexes, known as polyplexes formed via electrostatic interactions 
between a polycation and the negatively charged nucleic acid, such as 
the well-known synthetic non-degradable polyethyleneimine. When 
forming a polyplex with chitosan, the presence of a primary amine group 
on the glucosamine repeating unit enables control over the charge 
density. This control is dependent on both the degree of acetylation 
and the pH. These properties have led to the successful application 
of chitosan in non-viral gene delivery24 for purposes such as (1) gene 
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silencing (siRNA, shRNA), (2) compensating for defective genes, and 
(3) producing beneficial proteins or vaccines (DNA). Chitosan under 
slightly acidic conditions interacts with nucleic acids such as DNA or 
siRNA, leading to condensation of the nucleic acids into nanoparticles. 
This technique was successfully used for the formulation of a siRNA drug 
delivery system according to an ionic gelation process.25 Additionally, the 
biocompatibility and low toxicity of chitosan allow it to be used in vivo.26 
To afford charge permanency and solubility27 in a wider pH range similar 
to other cationic synthetic polymers such as poly-l-lysine, quaternization 
of the chitosan primary amine was investigated.28 The quaternary amine 
was typically generated by reaction with methyl iodide followed by the 
substitution of the iodide counter-ion with a chloride ion by an ion-
exchange process. The resulting N,N,N-trimethyl chitosan chloride (TMC) 
is the most frequently reported quaternized chitosan in the literature 
used for transfection in gene therapy applications.29 Quaternization of 
chitosan improved the stability of ionic complexes relative to those based 
on pure chitosan. Further chitosan derivatizations allowed improvement 
of the TMC properties. For example, a combination of quaternization 
and grafting of thiol on TMC yields mucoadhesive properties of TMC 
by disulfide formation with mucin proteins of the cell membrane.30 
Another example is the conversion of some primary amines in chitosan 
into carboxylic acids by reaction with succinic anhydride, which leads 
to improved solubility in neutral aqueous media.31 The collected acid-
bearing chitosan shows a higher solubility into water when at least 
20 mol% of the primary amines are converted into carboxylic acids. 
Despite the fact the stability of the complex of carboxylated chitosan 
with DNA was shown to be weaker than with pure chitosan, a better 
transfection efficiency was observed. 
The grafting of polymers or functional groups to chitosan is another 
option to improve gene delivery. The grafting of additional polymers or 
functional groups can lead to a better solubility and improved buffering 
capacity compared to unmodified chitosan. For example, the introduction 
of secondary and tertiary amino groups was shown to improve the 
transfection efficiency of chitosan.34 This one-step synthesis was based 
on the grafting of a carboxylic acid-bearing imidazole onto chitosan 
by amide formation, mediated by 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC). This simple and reproducible process improved 
both the solubility and the buffering capacity of the synthesized 
chitosan derivatives. 
Chitosan Derivatives for Drug Delivery
Recent development efforts within the pharmaceutical industry have 
resulted in a number of highly hydrophobic, and thus poorly water 
soluble active pharmaceutical ingredient candidates (i.e., BCS Class II 
and IV drug candidates). This lack of solubility considerably reduces the 
bioavailability of a drug candidate and complicates its development, 
preventing commercialization. Targeted nanocarriers can be used to 
encapsulate hydrophobic drug candidates, allowing for intravenous 
administration.35 Derivatized chitosan has been shown to be an 
attractive candidate for hydrophobic drug encapsulation. The grafting of 
hydrophobic moieties onto the chitosan backbone gave the synthesized 
polymer amphiphilic properties. This amphiphilic copolymer was 
shown to self-organize into micelles, with the drug solubilized in the 
hydrophobic core. Alkyl chains were initially grafted to the chitosan by 
reacting aliphatic aldehydes with the primary amine in the chitosan 
backbone, to form the corresponding Schiff base. This was followed by 
reduction with NaBH4.36–37 This strategy successfully enabled the grafting 
of C3, C5, C6, C8, and C12 alkyl chains to chitosan.38–40 Amphiphilic 
properties can be more precisely tuned by grafting both hydrophobic 
and hydrophilic components on a single chitosan backbone. Sequential 
grafting of octyl chains by reductive amination followed by the grafting 
of sulfate was also successfully achieved.41 The grafting of aromatic 
rings, namely 2-carboxybenzoyl groups or phtalimide groups, has also 
been investigated.42–43
The use of renewable materials for the modification of chitosan has 
also been demonstrated. Here, fatty acids were grafted to chitosan 
using a coupling reaction between the primary amine of chitosan and 
the carboxylic acid of the fatty acid mediated by EDC in a methanol 
and water solution.44–45 Using this technique, saturated stearic acid and 
unsaturated lineoic acid were successfully grafted onto oligochitosan. 
These derivatives were then modified with cholanic acid and cholesterol. 
Modified glycol-chitosan with 5-β-cholanic acid has been extensively 
studied both in vivo and in vitro as a carrier for docetaxel and paclitaxel.46,47 
Similarly, tocopherol-PEG-carboxylic acid has successfully been grafted 
onto chitosan.48 
Chitosan can also be modified with synthetic side-chains, particularly 
with biocompatible and hydrophobic aliphatic polyesters. The grafting 
of poly(ε-caprolactone) (PCL) was largely investigated for the synthesis of 
amphiphilic biocompatible chitosan based copolymers by both “grafting 
from” and “grafting to” techniques (Figure 2).49–50 In the “grafting from” 
technique, the polymerization of ε-caprolactone was initiated directly 
by the primary amine, or the hydroxyl groups, present on the chitosan 
chain. In the case of the “grafting to” technique, polymer chains bearing 
an appropriate functional group at one chain-end were grafted onto the 
primary amine or hydroxyl groups of chitosan.51
Polymerization Coupling
Grafting from Grafting to
n n
Figure 2. Illustration of the “grafting from” and “grafting to” techniques.
A selective initiation of the polymerization or grafting of a preformed 
polymer chain, exclusively by the hydroxyl groups can be reached if 
the primary amines are protected before reaction and deprotected 
afterwards.50,52–53 Remarkably, the chitosan primary amines can 
be protected by formation of a stable electrostatic complex with 
methylsulfonic acid, which is easily removed by precipitation in a 
phosphate buffer after polymerization. The reaction of chitosan with 
phthalic anhydride is another way to efficiently protect the primary amine 
groups. Such protection also improves the solubility of chitosan in organic 
solvents, namely dimethylformamide.54 Ester or urethane links are two 
examples of organic functions used for the grafting of PCL terminated by 
a carboxylic acid55 or an isocyanate group,54 respectively, onto hydroxyl 
groups of phthalimide-chitosan (Figure 3).
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Figure 3. Grafting PCL onto phtalimide-protected chitosan.
Compared to the “grafting from” technique, the “grafting to” technique 
was shown to demonstrate better control of the number and molecular 
weight of the PCL grafts onto chitosan. The grafting of polymer chains 
onto chitosan is not limited to PCL. The grafting of PEG chains onto 
chitosan is widely described in the literature.51,56 Recently, carboxylic 
acid-terminated PEG chains were grafted onto the primary amines of 
chitosan. The resulting grafted copolymer showed a reduced cytotoxicity 
compared to unaltered chitosan.51 Heterografted chitosan containing 
both PCL and PEG pendant chains was synthesized by Liu, et al. by 
simultaneous grafting of carboxylic acid-terminated PEG and PCL onto 
the hydroxyl group of phthalimide-chitosan leading to finely tuned 
amphiphilic properties.57
Finally, glucosamine58 (GlcNH2), the deacetylated monomer unit of 
chitosan, can be advantageously used to decorate nanoparticles for 
delivery of antibacterial and anticancer drugs.59–60 Indeed, GlcNH2 is 
known to be toxic to several malignant cell lines like human hepatoma, 
prostate, leukemia and breast cancer cells.61–64 Hence, GlcNH2 might 
be a promising target for the treatment of malignant cancer due to its 
inhibitory effect on transglutaminase 2 (TGase2), which contributes to 
drug resistance.62 GlcNH2 has also been used as a ligand in a kidney-
targeted drug delivery system for delivery of prednisolone leading to an 
increase in concentration of prednisolone in vivo.65 
Conclusions 
Chitosan has received considerable attention as a functional biopolymer 
for diverse pharmaceutical and biomedical applications. Chitosan 
is a nontoxic, biocompatible, and biodegradable polymer. It can be 
formulated as a nanocarrier using ionic interactions, leading to drug-
loaded colloidal systems with mucoadhesive and remarkable permeation-
enhancing properties. Additionally, this pH-sensitive polysaccharide can 
also be formulated as a hydrogel. 
The cationic properties of chitosan have enabled its extensive use 
for gene delivery. While nucleic acid-loaded chitosan nanoparticles 
fabricated from native chitosan have shown low buffering capacity and 
limited stability, chemically modified chitosan can help to improve in vivo 
transfection efficiency via: (1) quaternization to improve nanoparticle 
solubility and stability, (2) grafting of polymer chains to improve 
endosomal escape, or (3) grafting of ligands for specific cell targeting. 
When a hydrophobic moiety is conjugated to chitosan, the resulting 
polymer can self-assemble and encapsulate a poorly soluble drug. 
Grafting a steroid, fatty acid, or PCL onto chitosan or glycol chitosan can 
also lead to nanocarriers that are useful for drug delivery, in particular 
passive or active targeting of anticancer drugs to tumors.
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High Purity Chitosans (White Mushroom Origin)
Name Molecular Weight [MV] Degree of Acetylation Prod. No.
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740063-5G
140,000-220,000 ≤40 mol. % 740179-1G
740179-5G
40,000-60,000 ≤40 mol. % 746134-1G
746134-5G
Chitosans (Animal Origin)
Name Inherent Viscosity (cP ) Degree of Deacetylation Prod. No.
Chitosan 20-300  at 25 °C 75-85% 448869-50G
448869-250G
200-800  at 25 °C 75-85% 448877-50G
448877-250G
800-2000  at 25 °C >75% 419419-50G
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>200  at 20 °C ≥ 75% 417963-25G
417963-100G
Chitosan oligosaccharide lactate - > 90% 523682-1G
523682-10G
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yy End-group functionalized 
 - Carboxylic acid, amino, biotin for protein conjugation
 - Methoxy for non-binding
yy Nanoparticle sizes from 5 nm to 50 nm
yy 3 or 5 kDa PEG lengths
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• Biodegradable Polymers: polylactide and polyglycolide 
(PLA, PGA, PLGA), RESOMER®, and chitosan
• Hydrophilic Polymers: PEGs, poly(2-oxazoline), PNIPAM
• Conjugated Nanomaterials: Au, Ag, iron oxide 
nanoparticles, graphene oxide, and carbon nanotubes
• Broad Selection of Polymerization Tools: monomers, 
initiators, and CRP agents
